SCHEMBL4417962

SCHEMBL4417962

CC(=O)c1ccc(S(=O)(=O)N2CC3C(CNC(=O)c4ccc(N5CCOCC5)c(F)c4)C3C2)cc1

nearest known ligand 0.50

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.50
SLC6A9 P48067 4/20 0.49
USP30 Q70CQ3 4/20 0.48
NPC1 O15118 1/20 0.46
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
HTT P42858 2/20 0.45
LMNA P02545 3/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
KDM4E B2RXH2 1/20 0.45
POLB P06746 1/20 0.44
HPGD P15428 1/20 0.44
HSD17B10 Q99714 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4419964 0.93 KDM4C (0.50) ALDH1A1USP30NPC1MEN1KMT2A
SCHEMBL4415073 0.92 L3MBTL1 (0.50) ALDH1A1USP30MEN1KMT2ASMN1; SMN2
SCHEMBL4423692 0.92 USP30 (0.47) ALDH1A1SLC6A9USP30NPC1MEN1
SCHEMBL4414932 0.91 USP30 (0.48) ALDH1A1USP30NPC1MEN1KMT2A
SCHEMBL4425187 0.91 LMNA (0.55) ALDH1A1USP30NPC1MEN1KMT2A
SCHEMBL4419256 0.91 MAOA (0.50) ALDH1A1USP30NPC1MEN1KMT2A
SCHEMBL4415522 0.91 KDM4C (0.48) ALDH1A1USP30NPC1MEN1KMT2A
SCHEMBL4418887 0.90 SMN1; SMN2 (0.48) ALDH1A1USP30NPC1MEN1KMT2A
SCHEMBL4425266 0.89 USP30 (0.50) ALDH1A1SLC6A9USP30NPC1MEN1
SCHEMBL4415447 0.89 NPC1 (0.46) ALDH1A1SLC6A9USP30NPC1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1680124-A4 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2009-05-13 EP claimed
JP-2007508374-A 2007-04-05 JP claimed
EP-1680124-A2 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS Pfizer Products Incorporated (US) 2006-07-19 EP claimed
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC. 2005-05-05 US claimed
WO-2005037216-A2 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PRODUCTS INC. (US) 2005-04-28 WO claimed
EP-1680124-B1 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2017-05-31 EP disclosed
US-7473787-B2 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC (US) 2009-01-06 US disclosed
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC. 2005-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors SLC6A5, SLC1A5, SLC6A3 ALDH1A1 3166/4885SLC6A9 9/4885USP30 4095/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.